Biogen Inc logo

Biogen Inc

XSWX:BIIB (USA)  
CHF 232.00 (0%) Apr 1
P/E:
13.28
P/B:
2.99
Market Cap:
CHF 40.08B ($ 43.81B)
Enterprise V:
CHF 41.65B ($ 45.52B)
Volume:
-
Avg Vol (2M):
-
Also Trade In:
Volume:
-
Market Cap CHF:
40.08B
Market Cap $:
43.81B
PE Ratio:
13.28
Avg Vol (2M):
-
Enterprise Value CHF:
41.65B
Enterprise Value $:
45.52B
PB Ratio:
2.99

Business Description

Description
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021, followed by Leqembi in January 2023.
Name Current Vs Industry Vs History
Cash-To-Debt 0.74
Equity-to-Asset 0.55
Debt-to-Equity 0.49
Debt-to-EBITDA 1.5
Interest Coverage 11.77
Piotroski F-Score 6/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 4.35
Distress
Grey
Safe
Beneish M-Score -2.22
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Momentum Rank

Name Current Vs Industry Vs History

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 2.99
Quick Ratio 2.58
Cash Ratio 1.49
Days Inventory 210.85
Days Sales Outstanding 72.52
Days Payable 73.61

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio 6.1

Financials (Next Earnings Date:2023-05-03 Est.)

XSWX:BIIB's 30-Y Financials

How Biogen Inc (XSWX:BIIB) Makes Its Money

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
To

Annualized Return %

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %

Symbol
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014

Biogen Inc Executives

Details

Valuation chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil CHF) 9,676.513
EPS (TTM) (CHF) 0
Beta 0
Volatility % 30.56
14-Day RSI 0
14-Day ATR (CHF) 0
20-Day SMA (CHF) 0
12-1 Month Momentum % 0
52-Week Range (CHF) 232 - 232
Shares Outstanding (Mil) 152.34

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 6
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Biogen Inc Filings

Document Form Filing Date
No Filing Data

Biogen Inc Stock Events

Event Date Price(CHF)
No Event Data

Biogen Inc Frequently Asked Questions

What is Biogen Inc(XSWX:BIIB)'s stock price today?
The current price of XSWX:BIIB is CHF232.00. The 52 week high of XSWX:BIIB is CHF232.00 and 52 week low is CHF232.00.
When is next earnings date of Biogen Inc(XSWX:BIIB)?
The next earnings date of Biogen Inc(XSWX:BIIB) is 2023-05-03 Est..
Does Biogen Inc(XSWX:BIIB) pay dividends? If so, how much?
Biogen Inc(XSWX:BIIB) does not pay dividend.

Press Release

Subject Date
No Press Release